FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
-------------	------	-------	--

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
In a torrest and day

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

ee Instruction 1																			
Name and Address of Reporting Person* Evans John M.				2. Issuer Name and Ticker or Trading Symbol Beam Therapeutics Inc. [BEAM]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
Evans John M.								-		-			Director			10% Owner			
(Last) (First) (Middle)					O Data of Fauli ant Transaction (Manth (David) and							1			le		ther (specify		
•	,	,		09/30/2024 (Month/Day/Year)								CEO							
238 MAIN STREET																			
IN STREE.	4 If A	4. If Amendment, Date of Original Filed (Menth/Dov/Mear)) 6	6 Individual or Joint/Group Filing (Check Applicable								
			7. " /	4. II Amendment, Date of Original Filed (Month/Day/Year)									Line)						
IDGE M	A 0	2142											1	_			•		
																Nore tha	an One F	Reporting	g
(St	rate) (Ž	Zip)																	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)			2A. Deemed Execution Date, if any (Month/Day/Year		Date,	Code (Instr		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and				Beneficially Owned			6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code	v	Amo	ount	(A) or (D)	Pri	Price		Reported Transaction(s) (Instr. 3 and 4)					
Common Stock		09/30/2024			S ⁽¹			60	0,000	D	D \$24.60		938,659(59 ⁽³⁾	D			\neg
							Ì						T					By Jol	hn
																		M. Ev	
Common Stock														103,	000]	I		- 1
																		Trust	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Instr. 3) 3. Transaction Date (Month/Day/Year) (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year)			Transaction Code (Instr. 8) Securi Acqui (A) or Dispo		Expiration Date (Month/Day/Year) Amount of Securities Underlying Derivative or posed Securities (Inderlying Derivative Security (In 3 and 4)			int of rities rlying ative rity (Instr.	8. Price of Derivative Security (Instr. 5)		Reported		Ownership Form: Direct (D)		. Nature Indirect eneficial wnership nstr. 4)				
					(Instr	. 3, 4													
										Amount	1								
			Code	v	(A)						itle	or Number of Shares							
	Ind Address of John M. (Final THERAL NATREE IN STREE IN STREET IN STRE	Ind Address of Reporting Person John M. (First) (IMAN THERAPEUTICS INC.) IN STREET IDGE MA 0 (State) (Z Table Security (Instr. 3) Stock Tal 2. Conversion or Exercise Price of Derivative (Month/Day/Year)	Table II - Derivation (Bond Month/Day/Year) Table II - Derivation (Month/Day/Year) Table II - Derivation (Month/Day/Year) 3. Transaction Date (Month/Day/Year) [Month/Day/Year]	Address of Reporting Person* Ichin M. (First) (Middle) AM THERAPEUTICS INC., N STREET IDGE MA 02142 (State) (Zip) Table I - Non-Derivative Security (Instr. 3) Security (Instr. 3) 2. Transaction Date (Month/Day/Year) Stock Table II - Derivative Security (e.g., puts, call for Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) A Deemed Execution Date, if any (Month/Day/Year) (Month/Day/Year) 4. Transaction Date (Month/Day/Year) Security (Month/Day/Year) A Deemed Execution Date, if any (Month/Day/Year) (Month/Day/Year)	Conversion or Exercise Price of Derivative Security (Month/Day/Year) Conversion Or Exercise Price of Derivative Security (Mon	Continue Continue	Address of Reporting Person* Column Column	Conversion or Exercise Price of Derivative Securities Acquired (e.g., puts, calls, warrants, option or Exercise Price of Derivative Security (Month/Day/Year)	Code V American Conversion Convers	Code Namount N	Address of Reporting Person Cohn M. Circle Conversion Code Code	Address of Reporting Person Only 10 Mm. (First) (Middle) (MTHERAPEUTICS INC., N STREET IDGE MA 02142 (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Executing Month/Day/Year (Month/Day/Year) Security (Instr. 3) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) Stock Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3) Code V Amount (A) or Price of Original Filed (Month/Day/Year) (Conversion Date (e.g., puts, calls, warrants, options, convertible see (e.g., puts, calls, warrants, options,	Address of Reporting Person for Manney (First) (Middle) (First) (Middle) (M	Address of Reporting Person of Man M. (First) (Middle) (MT THERAPEUTICS INC., N STREET A. If Amendment, Date of Original Filed (Month/Day/Year)	Conversion Con	Address of Reporting Person Cohm M.	Conversion Con	Comment Comm	Code Individual of Amount of Barborita Code Individual of Amount of Barborita Code Individual of Amount of Barborita Individual of Amount of Barborita Individual of Amount of Individual of Amount of Individual of Amount of Individual of I

Explanation of Responses:

- 1. These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$24.26 to \$25.24, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 3. Includes 316 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2024.

By: /s/ Christine Bellon, 10/02/2024 Attorney-in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.